Robert Radinsky, PhD

Robert Radinsky, Ph.D. is Vice President, Global Head, Oncology External Innovation at J&J Innovative Medicine. In this role, the team is responsible for identifying and fostering innovation that supports the Oncology Therapeutic Area / Disease Area Stronghold strategies.  Over the last 10 years, the team has been responsible for over 220 executed deals including licenses, acquisitions and agreements.  Prior to the current  role, Robert represented the Oncology Therapeutic Area at  Johnson & Johnson Innovation, North America. Preceding this role, he led Discovery Research, Oncology Therapeutic Area for Janssen/J&J Research & Development.

Robert has had a very successful oncology research career in both academics and industry. Prior to joining J&J, he was Executive Director, Oncology Research at Amgen Inc., where he led groups at multiple research sites including Thousand Oaks, California, and Cambridge, Massachusetts. He was responsible, in part, for research and/or pharmacology for numerous active targeted therapeutic anti-cancer programs (protein, small molecule and nanotechnology modalities), culminating with multiple candidates in clinical trials and an approved drug, Panitumumab, for the treatment of colorectal carcinoma.

Before joining industry 25 years ago, Robert was on the faculty at The University of Texas MD Anderson Cancer Center in Houston, Texas first serving as an American Cancer Society Postdoctoral Research Fellow in the Department of Cell Biology and eventually ascending to a tenured Associate Professor in the Department of Cancer Biology. He continued as an Adjunct Professor at the MD Anderson Cancer Center after joining the industry.

Robert has published more than 145 peer-reviewed articles, holds multiple patents, and is a present/past member of numerous societies, including the American Association for Cancer Research, Board of Directors for the Metastasis Research Society, the American Association for the Advancement of Science, the Scientific Advisory Board and the Aspen Cancer Conference. He is/was an Editorial Member and/or ad hoc reviewer for more than 20 scientific journals and has served on review panels for a number of granting agencies, including the National Institutes of Health/National Cancer Institute, the Department of Defense Prostate and Breast Cancer Research Programs, and the Veterans Administration Merit Review Board.

Robert earned his doctorate in Molecular Biology and Microbiology from Case Western Reserve University School of Medicine in Cleveland, Ohio and Bachelor of Science degree in Cell and Developmental Biology from Purdue University in West Lafayette, Indiana.